Detection and measurement of thyroid hormone autoantibodies
First Claim
Patent Images
1. A non-radioisotopic method of determining canine T3AA in a patient sample comprising:
- (a) measuring the amount of Free T3 in a patient sample, wherein the sample is from a canine species, the Free T3 being attached as Free T3/T3AA complex when T3AA is present in the patient sample together with Free T3 unattached to T3AA;
(b) treating the patient sample with a non-radioisotopic precipitating or binding agent to precipitate or bind Free T3/T3AA complex thereby forming a complex of precipitated or bound Free T3/T3AA complex;
(c) suspending the non-radioisotopic precipitate or bound complex, and at least one of;
(i) measuring the amount of Free T3/T3AA complex in suspended non-radioisotopic precipitate or bound complex using a non-radioisotopic label, and(ii) subtracting the measurement of i) from a) wherein the result of ii) is directly proportional to the amount of Free T3/T3AA complex thereby determining the amount of T3AA in the patient sample;
or(iii) measuring Free T3 in supernatant or surrounding fluid of the non-radioisotopic precipitate or bound complex using a non-radioisotopic label;
(iv) subtracting the measurement of iii) from a) wherein the result of iv) is indirectly proportional to the amount of Free T3/T3AA complex thereby determining the amount of T3AA in the patient sample; and
effecting detection with a sensitivity in a range between 1 picogram per mL and up to about 1 femtogram per mL.
2 Assignments
0 Petitions
Accused Products
Abstract
A non-radioisotopic method detects T3AA and T4AA thyroid autoantibodies in a sample from a non-human species such as the canine species. Antibodies and autoantibodies are bound, and a precipitated or bound antigen-antibody or antigen-autoantibody complex is formed. The supernatant or surrounding fluid of the bound or precipitated antigen-antibody or antigen-autoantibody complex is then removed. The thyroid activity of the bound complex, precipitate, supernatant or surrounding fluid is measured. The thyroid analyte is at least one of T3, Free T3, T4 or Free T4.
25 Citations
13 Claims
-
1. A non-radioisotopic method of determining canine T3AA in a patient sample comprising:
-
(a) measuring the amount of Free T3 in a patient sample, wherein the sample is from a canine species, the Free T3 being attached as Free T3/T3AA complex when T3AA is present in the patient sample together with Free T3 unattached to T3AA; (b) treating the patient sample with a non-radioisotopic precipitating or binding agent to precipitate or bind Free T3/T3AA complex thereby forming a complex of precipitated or bound Free T3/T3AA complex; (c) suspending the non-radioisotopic precipitate or bound complex, and at least one of; (i) measuring the amount of Free T3/T3AA complex in suspended non-radioisotopic precipitate or bound complex using a non-radioisotopic label, and (ii) subtracting the measurement of i) from a) wherein the result of ii) is directly proportional to the amount of Free T3/T3AA complex thereby determining the amount of T3AA in the patient sample; or (iii) measuring Free T3 in supernatant or surrounding fluid of the non-radioisotopic precipitate or bound complex using a non-radioisotopic label; (iv) subtracting the measurement of iii) from a) wherein the result of iv) is indirectly proportional to the amount of Free T3/T3AA complex thereby determining the amount of T3AA in the patient sample; and effecting detection with a sensitivity in a range between 1 picogram per mL and up to about 1 femtogram per mL. - View Dependent Claims (6, 7, 8, 11)
-
-
2. A non-radioisotopic method of determining canine T3AA in a sample:
-
(a) measuring the amount of Free T3 in a patient sample, wherein the sample is from a canine species, the Free T3 being attached as Free T3/T3AA complex when T3AA is present in the patient sample together with Free T3 unattached to T3AA; (b) treating the patient sample with a non-radioisotopic precipitating or binding agent to precipitate or bind Free T3/T3AA complex thereby forming a complex of precipitated or bound FreeT3 and T3AA; (c) suspending the non-radioisotopic precipitate or bound complex, and at least one of; (i) measuring the amount of Free T3/T3AA complex in suspended non-radioisotopic precipitate or bound complex using a non-radioisotopic label; and (ii) subtracting the measurement of i) from a) wherein the result of ii) is directly proportional to the amount of Free T3/T3AA complex thereby determining the amount of T3AA in the patient sample; or (iii) measuring Free T3 in supernatant or surrounding fluid of the precipitate or bound complex using a non-radioisotopic label; and (iv) subtracting the measurement of iii) from a) wherein the result of iv) is indirectly proportional to the amount of FreeT3/T3AA complex thereby determining the amount of T3AA in the patient sample; and effecting detection of a), c) i) or c) iii) by employing non-radioisotopic chemiluminescence, and including a bioluminescent detector and microparticles for immobilizing Free T3 as a solid phase, thereby to obtain a non-radioisotopic determination of T3AA. - View Dependent Claims (4, 9, 12)
-
-
3. A non-radioisotopic method of determining canine T3AA in a sample
(a) measuring the amount of Free T3 in a patient sample, wherein the sample is from a canine species, the Free T3 being attached as Free T3/T3AA complex when T3AA is present in the patient sample together with Free T3 unattached to T3AA; -
(b) treating the patient sample with a non-radioisotopic precipitating or binding agent to precipitate or bind FreeT3/T3AA complex thereby forming a complex of precipitated or bound FreeT3 and T3AA; (c) suspending the non-radioisotopic precipitate or bound complex, and at least one of; (i) measuring the amount of Free T3/T3AA complex in suspended non-radioisotopic precipitate or bound complex using a non-radioisotopic label, and (ii) subtracting the measurement of i) from a) wherein the result of ii) is directly proportional to the amount of FreeT3/T3AA complex thereby determining the amount of T3AA in the patient sample; or (iii) measuring Free T3 in supernatant or surrounding fluid of the precipitate or bound complex using a non-radioisotopic label; and (iv) subtracting the measurement of iii) from a) wherein the result of iv) is indirectly proportional to the amount of FreeT3/T3AA complex thereby determining the amount of T3AA in the patient sample; and (d) effecting detection of a), c) i) or c) iii) by employing a non-radioisotopic detection thereby to obtain a non-radioisotopic determination of T3AA. - View Dependent Claims (5, 10, 13)
-
Specification